In the current study, we demonstrate that targeting Mcl-1 during senescence-inducing doxorubicin treatment in otherwise senescence-resistant cells causes activation of the ROS-dependent DNA damage response (DDR), which is critical for the induction of senescence in cancer [11]. The gene discussed is MCL1; the disease is cancer.